Article Sidebar

Published
April 28, 2024
Download
PDF
Statistic
Read Counter : 490 Download : 414

Main Article Content

Abstract

Background: This study aimed to evaluate the effectiveness of the Rubella vaccine in children
who have received the MMR vaccine.
Material and Methods: The study design is a case - control study. This study was performed
in Thi-Qar Province, Iraq, from Sep-2023 to Jan-2024. 176 children were included (117 cases and
59 controls), aged less than thirteen years. The ELISA technique was used to detect anti-Rubella
Virus IgG.
Results: The seroprevalence of Rubella Virus IgG in the case group was positive in 110 (94.0%)
of 117 children. While within the control group, 29 (49.2%) of 59 children were positive, there
was a significant difference in IgG titer between both groups (p-value <0.001), but according to
sex, there were no significant differences between males and females in both groups (p- value =
0.957 and p- value = 0.711, respectively). The results found a positive correlation with INF-γ (r =
0.921, p- value < 0.001), but no correlation with IL-6 (r = 0.018, p- value = 0.849).
Conclusions: Our study concludes that the Rubella vaccine is potent for children who have been
vaccinated, with effectiveness reaching 94%, which is a very good percentage for controlling
disease. We recommend increasing vaccine coverage in Thi-Qar province.

Keywords

Rubella virus IgG MMR vaccine IL-6 IFN-γ

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Winter, A.K. and W.J. Moss, Rubella. The Lancet, 2022. 399(10332): p. 1336-1346.
  2. Das, P.K. and M. Kielian, Molecular and structural insights into the life cycle of rubella virus.
  3. Journal of virology, 2021. 95(10): p. 10.1128/jvi. 02349-20.
  4. ICTV, 2022 Master Species List (MSL38) https://ictv.global/msl, 2023(accessed Oct 14,
  5. .
  6. Pagonendji, M., et al., Rubella epidemiology in the Central African Republic, 2015-2016 and
  7. molecular characterization of virus strains from 2008-2016. International Journal of Infectious
  8. Diseases, 2022. 116: p. S116.
  9. Voigt, E.A., et al., Polymorphisms in the Wilms Tumor Gene Are Associated With
  10. Interindividual Variations in Rubella Virus–Specific Cellular Immunity After Measles-MumpsRubella II Vaccination. The Journal of Infectious Diseases, 2018. 217(4): p. 560-566.
  11. Brooks, G., et al., Jawetz, Melnick & Adelbergs medical microbiology. th 28 Ed. 2019, United
  12. States, McGraw-Hill.
  13. Haralambieva, I.H., et al., Transcriptional signatures associated with rubella virus-specific
  14. humoral immunity after a third dose of MMR vaccine in women of childbearing age. Eur J Immunol,
  15. 51(7): p. 1824-1838.
  16. Ali Qanbar, M., A.K. Jasim, and A.A. Mahmood, Assessment of immunization session
  17. practices in primary health care centers in Al-Najaf province. J Public Health Afr, 2023. 14(9): p.
  18. Lambert, N.D., et al., Polymorphisms in HLA-DPB1 are associated with differences in rubella
  19. virus–specific humoral immunity after vaccination. The Journal of Infectious Diseases, 2015. 211(6):
  20. p. 898-905.
  21. Zimmerman, L.A., et al., Progress in control and elimination of rubella and congenital
  22. rubella syndrome worldwide, 2012-2020/Progres realises pour combattre et eliminer la rubeole et le
  23. syndrome de rubeole congenitale dans le monde, 2012-2020. Weekly Epidemiological Record, 2022.
  24. (6): p. 33-41.
  25. Lambert, N., et al., Rubella. Lancet, 2015. 385(9984): p. 2297-307.
  26. Kirby, T., Rubella is eliminated from the Americas. Lancet Infect Dis, 2015. 15(7): p. 768-9.
  27. Ferrari, C., et al., Rubella Vaccine Uptake among Women of Childbearing Age in Healthcare
  28. Settings. Healthcare (Basel), 2023. 11(22).
  29. Alonge, O.D., et al. Long-term Neutralizing Antibody Levels Against Measles and Rubella
  30. Viruses among Adults with Three Doses of Measles-Mumps-Rubella Vaccine. in Open Forum
  31. Infectious Diseases. 2024. Oxford University Press.
  32. CDC, Child and Adolescent Immunization Schedule by Age.
  33. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html#table-1, 2023(Accessed, jan
  34. 2024).
  35. Brunton, J.S., et al., Efficacy of Rubella Vaccination after Co-Inoculation with Rhogam.
  36. Viruses, 2023. 15(9): p. 1782.
  37. WHO, Rubella reported cases and incidence.
  38. https://immunizationdata.who.int/pages/incidence/rubella.html?CODE=Global&YEAR=,
  39. (accessed Oct 9, 2023).
  40. Khadair, H.Y. and S.F.M.H. Al-Shaikh, Assessment of Immune Susceptibility to Rubella
  41. among Pregnant Women in Hilla City. Medical Journal of Babylon, 2019. 16(4).
  42. Fayad, A.N. and I.N. Abid, ELISA and ICT Techniqes in the detection of anti-Rubella virus
  43. Antibodies in Aborted women in Al-Nasiriyah city, Thi-Qar, Iraq. University of Thi-Qar Journal,
  44. 12(4): p. 1-10.
  45. Yang, L., B.T. Grenfell, and M.J. Mina, Waning immunity and re-emergence of measles and
  46. mumps in the vaccine era. Curr Opin Virol, 2020. 40: p. 48-54.
  47. Seagle, E.E., et al., Measles, mumps, and rubella antibody patterns of persistence and rate of
  48. decline following the second dose of the MMR vaccine. Vaccine, 2018. 36(6): p. 818-826.
  49. Kakoulidou, M., et al., Kinetics of antibody and memory B cell responses after MMR
  50. immunization in children and young adults. Vaccine, 2013. 31(4): p. 711-717.
  51. Hansashree, P., et al., Long-term Seroprotection Rates Following Second Dose of Measles as
  52. MMR Vaccine at 15 months in Indian Children. Indian Pediatrics, 2018. 55(5): p. 405-407.
  53. Crooke, S.N., et al., Seroprevalence and durability of rubella virus antibodies in a highly
  54. immunized population. Vaccine, 2019. 37(29): p. 3876-3882.
  55. Mora-García, G.J., et al., [The seroprevalence of IgG antibodies against rubella (German
  56. measles) in 10-49 year-old women from Cartagena, Colombia]. Rev Salud Publica (Bogota), 2011.
  57. (2): p. 288-97.
  58. Gupta, M., et al., Seroprevalence of measles, mumps & rubella antibodies among 5-10 years
  59. old children in north India. Indian J Med Res, 2019. 149(3): p. 396-403.
  60. Gupta, R., N. Saxena, and P. Gupta, Determination of ELISA reactive mumps IgG antibodies
  61. in MMR vaccine recipients in comparison with MMR vaccine naive children: A cross sectional study.
  62. Scripta Medica, 2021. 52(3): p. 174-180.
  63. Wanlapakorn, N., et al., Antibodies to measles, mumps, and rubella virus in Thai children
  64. after two-dose vaccination at 9 months and 2.5 years: A longitudinal study. Vaccine, 2020. 38(24):
  65. p. 4016-4023.
  66. Kukule, L., IgG protection status for humoral immune response to MMR vaccine among the
  67. Norwegian population of children and method assessment of MMR-Multi-Plex Immunoassay. 2022,
  68. Norwegian University of Life Sciences, Ås.
  69. Madi, N., et al., Assessment of immune status against measles, mumps, and rubella in young
  70. Kuwaitis: MMR vaccine efficacy. J Med Virol, 2020. 92(8): p. 963-970.
  71. Crooke, S.N., et al., Associations between markers of cellular and humoral immunity to
  72. rubella virus following a third dose of measles-mumps-rubella vaccine. Vaccine, 2020. 38(50): p.
  73. -7904.
  74. Wang, X., et al., Do adolescents need a rubella vaccination campaign? Rubella serosurvey
  75. among healthy children in Hangzhou, China. Hum Vaccin Immunother, 2023. 19(2): p. 2254536.
  76. Terada, K., et al., Rubella specific cell-mediated and humoral immunity following vaccination
  77. in college students with low antibody titers. Vaccine, 2015. 33(45): p. 6093-8.
  78. Gastañaduy, P.A., et al., Public health responses during measles outbreaks in elimination
  79. settings: Strategies and challenges. Human Vaccines & Immunotherapeutics, 2018. 14(9): p. 2222-
  80. Smetana, J., et al., Decreasing seroprevalence of measles antibodies after vaccination–
  81. possible gap in measles protection in adults in the Czech Republic. PLoS One, 2017. 12(1): p.
  82. e0170257.
  83. Guerra, F.M., et al., Waning of measles maternal antibody in infants in measles elimination
  84. settings - A systematic literature review. Vaccine, 2018. 36(10): p. 1248-1255.
  85. Hefele, L., et al., Seroprevalence of measles and rubella antibodies in vaccinated and
  86. unvaccinated infants in the Lao People's Democratic Republic. Int J Infect Dis, 2021. 108: p. 524-
  87. Lamrani Alaoui, H., et al., Rubella seroprevalence among pregnant women in the region of
  88. Rabat, Morocco: a cross-sectional study. BMJ Open, 2023. 13(6): p. e067842.
  89. Mensah, E.A. and S.O. Gyasi, Measles-Rubella Positivity Rate and Associated Factors in
  90. Pre-Mass and Post-Mass Vaccination Periods: Analysis of Uganda Routine Surveillance Laboratory
  91. Data. Advances in Public Health, 2022. 2022: p. 5080631.
  92. Muthiah, N., et al., Dynamics of maternally transferred antibodies against measles, mumps,
  93. and rubella in infants in Sri Lanka. International Journal of Infectious Diseases, 2021. 107: p. 129-
  94. Pedranti, M., et al., Measles and Rubella Seroprevalence Among Children and Adolescents of
  95. Córdoba, Argentina: A Cross-Section Study in the Context of the Elimination Program. Viral
  96. Immunol, 2023. 36(6): p. 429-434.
  97. Wanlapakorn, N., et al., Antibodies against measles and rubella virus among different age
  98. groups in Thailand: a population-based serological survey. PLoS One, 2019. 14(11): p. e0225606.
  99. Klein, S.L., A. Jedlicka, and A. Pekosz, The Xs and Y of immune responses to viral vaccines.
  100. Lancet Infect Dis, 2010. 10(5): p. 338-49.
  101. Sun, J., et al., Mumps-specific antibody persistence in children aged 3-7 years immunized with
  102. two doses of mumps-containing vaccines: A prospective cohort study in Jiangsu Province, China.
  103. Hum Vaccin Immunother, 2023. 19(1): p. 2166758.
  104. Verma, S.K., et al., Immunogenicity of measles-rubella vaccine administered under India’s
  105. Universal Immunization Programme in the context of measles–rubella elimination goal: A
  106. longitudinal study. Indian Journal of Medical Research, 2023. 157(4).
  107. Lambert, N.D., et al., Characterization of humoral and cellular immunity to rubella vaccine
  108. in four distinct cohorts. Immunol Res, 2014. 58(1): p. 1-8

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)